 1.2. The secondary end points of the study include; engraftment absolute neutrophil count over 500μl, unsupported platelet count over 20,000μl, donor chimerism at 2 and 4 weeks after HCT, secondary graft failure, acute and chronic graft-versus-host disease GVHD, lymphocyte subset recovery at 1, 2, 3, 6, and 12 months, cytomegalovirus CMV reactivationCMV disease, Epstein-Barr virus EBV reactivationpost-transplant lymphoproliferative disorder, transplantation-related mortality 100 day, 1 year, leukemia free survival, and overall survival. 